Table 4.

Effect of myricitrin and its SLN on plasma and urine levels of Na and K, FE Na, FE K, and relative mRNA expression of TGF-β and NF-κB in the kidney

Groups	Plasma Na (mEq/l)	Plasma K (mEq/l)	Urine Na (mEq/l)	Urine K (mEq/l)	FE Na (%)	FE K (%)
Control	171.25±1.65	5.52±0.28	136.33±11.86	75.50±5.90	0.525±0.016	9.54±1.07
Vehicle	170.40±2.63	5.28±0.37	138.50±12.58**	71.66±6.98**	0.602±0.100***	10.09±1.98***
Diabetes	173.33±2.02	5.10±0.28	185.33±12.97##	105.50±9.13##	1.277±0.138###	24.60±1.10###
Diabetes + myricitrin 1 mg/kg	174.00±1.68	5.25±0.12	170.50±10.50#	87.33±5.84*	0.847±0.023#**	14.38±0.89#***
Diabetes + myricitrin 3 mg/kg	173.66±6.76	5.10±0.23	136.33±7.02**	85.50±6.78*	0.687±0.100***	14.62±2.5#***
Diabetes + myricitrin 10 mg/kg	168.50±1.04	5.25±0.11	139.33±15.50**	70.25±2.21***	1.104±0.098###	17.87±0.83##**
Diabetes + myricitrin SLNs 1 mg/kg	180.25±5.75	5.55±0.17	166.33±10.96#	82.50±4.52*	0.720±0.069***	11.63±1.60***
Diabetes + myricitrin SLNs 3 mg/kg	171.75±3.37	5.70±0.10	125.33±6.17**	79.25±6.15**	0.535±0.045***	10.02±1.05***
Diabetes + myricitrin SLNs 10 mg/kg	169.25±3.94	5.47±0.08	135.50±13.02**	69.00±4.72***	0.961±0.100##*	15.18±1.70##***

Data are presented as mean±SEM; n=12; #P<0.05, ##P<0.01 and ###P<0.001 compared to the control, *P<0.05, **P<0.01, and ***P<0.001 compared to the diabetes group. SLN: Solid lipid nanoparticle, FE Na: Fractional excretion of sodium, FE K: Fractional excretion of potassium, NF-κB: Nuclear factor kappa B, TGF-β: Transforming growth factor-β